Equities analysts forecast that Sangamo Therapeutics Inc (NASDAQ:SGMO) will announce sales of $19.27 million for the current quarter, Zacks Investment Research reports. Four analysts have issued estimates for Sangamo Therapeutics’ earnings, with estimates ranging from $13.38 million to $22.60 million. Sangamo Therapeutics posted sales of $26.84 million during the same quarter last year, which would suggest a negative year over year growth rate of 28.2%. The firm is scheduled to announce its next quarterly earnings report on Thursday, February 27th.
On average, analysts expect that Sangamo Therapeutics will report full-year sales of $64.62 million for the current fiscal year, with estimates ranging from $52.00 million to $70.20 million. For the next financial year, analysts anticipate that the business will report sales of $111.07 million, with estimates ranging from $55.10 million to $240.50 million. Zacks’ sales averages are a mean average based on a survey of research analysts that that provide coverage for Sangamo Therapeutics.
Sangamo Therapeutics (NASDAQ:SGMO) last released its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported ($0.24) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.34) by $0.10. Sangamo Therapeutics had a negative return on equity of 30.33% and a negative net margin of 159.12%. The firm had revenue of $21.96 million during the quarter, compared to the consensus estimate of $12.16 million. During the same quarter in the previous year, the company posted ($0.13) earnings per share. The company’s quarterly revenue was down 6.8% on a year-over-year basis.
Several institutional investors and hedge funds have recently modified their holdings of SGMO. Quantitative Systematic Strategies LLC bought a new stake in shares of Sangamo Therapeutics in the second quarter worth $126,000. Steward Partners Investment Advisory LLC bought a new stake in Sangamo Therapeutics during the second quarter valued at about $50,000. Virginia Retirement Systems ET AL grew its holdings in Sangamo Therapeutics by 13.6% during the second quarter. Virginia Retirement Systems ET AL now owns 20,900 shares of the biopharmaceutical company’s stock valued at $225,000 after purchasing an additional 2,500 shares during the period. Creative Planning lifted its position in shares of Sangamo Therapeutics by 91.1% in the second quarter. Creative Planning now owns 55,104 shares of the biopharmaceutical company’s stock valued at $593,000 after acquiring an additional 26,265 shares in the last quarter. Finally, Bailard Inc. lifted its position in shares of Sangamo Therapeutics by 12.5% in the second quarter. Bailard Inc. now owns 175,600 shares of the biopharmaceutical company’s stock valued at $1,891,000 after acquiring an additional 19,500 shares in the last quarter. 70.78% of the stock is owned by institutional investors.
Shares of Sangamo Therapeutics stock opened at $10.80 on Monday. The stock has a fifty day simple moving average of $9.25 and a 200 day simple moving average of $10.21. Sangamo Therapeutics has a 12-month low of $6.26 and a 12-month high of $13.91. The company has a market capitalization of $1.25 billion, a P/E ratio of -15.43 and a beta of 2.79. The company has a current ratio of 4.77, a quick ratio of 4.77 and a debt-to-equity ratio of 0.10.
Sangamo Therapeutics Company Profile
Sangamo Therapeutics, Inc focuses on translating science into genomic medicines that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's zinc finger proteins (ZFPs) could be engineered to make zinc finger nucleases (ZFNs), proteins that could be used to modify DNA sequences by adding or knocking out specific genes or genome editing; and ZFP transcription factors (ZFP TFs) proteins that can be used to increase or decrease gene expression or gene regulation.
Featured Article: Insider Trading – What You Need to Know
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.